PCV33: COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN AND LOVASTATIN/EXTENDED-RELEASE NIACIN TO ACHIEVE LDLAND HDL GOAL USING NHANES DATA

Value in Health ◽

10.1016/s1098-3015(10)64147-2 ◽

2003 ◽

Vol 6 (3) ◽

pp. 319

Author(s):

EP Armstrong ◽

WM Zachry ◽

DC Malone

Keyword(s):

Cost Effectiveness ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

A Cost-Effectiveness Analysis of Guanfacine Extended-Release Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder

Value in Health ◽

10.1016/j.jval.2016.08.529 ◽

2016 ◽

Vol 19 (7) ◽

pp. A841

Author(s):

S Maeda ◽

K Shimozuma ◽

Y Takeda

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Cost Effectiveness ◽

Attention Deficit ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Hyperactivity Disorder ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data

Journal of Managed Care Pharmacy ◽

10.18553/jmcp.2004.10.3.251 ◽

2004 ◽

Vol 10 (3) ◽

pp. 251-258

Author(s):

Edward P. Armstrong ◽

Woodie M. Zachry ◽

Daniel C. Malone

Keyword(s):

Cost Effectiveness ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

PUK20 A COST EFFECTIVENESS ANALYSIS OF SOLIFENACIN COMPARED WITH EXTENDED-RELEASE TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER

Value in Health ◽

10.1016/s1098-3015(10)65151-0 ◽

2007 ◽

Vol 10 (6) ◽

pp. A319

Author(s):

HH Kang ◽

JY Bae ◽

SY Park ◽

HS Sohn

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysis

Clinical Therapeutics ◽

10.1016/s0149-2918(00)80041-7 ◽

2000 ◽

Vol 22 (3) ◽

pp. 362-370 ◽

Author(s):

Hemal Shah ◽

Kathleen Gondek

Keyword(s):

Ischemic Stroke ◽

Cost Effectiveness ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Extended-Release Formulations of Oxybutynin and Tolterodine for the Management of Urge Incontinence

PharmacoEconomics ◽

10.2165/00019053-200422160-00002 ◽

2004 ◽

Vol 22 (16) ◽

pp. 1047-1059 ◽

Author(s):

Dyfrig A Hughes ◽

Dominique Dubois

Keyword(s):

Cost Effectiveness ◽

Urge Incontinence ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Extended Release Formulations

Download Full-text

Cost-Effectiveness Analysis of Pramipexole Extended Release Monotherapy In Early Parkinson`S Disease

Value in Health ◽

10.1016/j.jval.2015.09.2466 ◽

2015 ◽

Vol 18 (7) ◽

pp. A757

Author(s):

D Belousov ◽

E Afanasieva

Keyword(s):

Cost Effectiveness ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Cost Effectiveness Analysis for the Use of Extended Release Quetiapine as Adjunctive Therapy in Mexican Adult Patients with Major Depressive Disorder Non-Responders to Antidepressant Treatment

Value in Health ◽

10.1016/j.jval.2013.08.1404 ◽

2013 ◽

Vol 16 (7) ◽

pp. A547

Author(s):

A.C. Polanco ◽

I.S.I. Ascencio ◽

A. Salazar ◽

L.A. González ◽

M. Pizarro ◽

...

Keyword(s):

Major Depressive Disorder ◽

Cost Effectiveness ◽

Depressive Disorder ◽

Adjunctive Therapy ◽

Extended Release ◽

Antidepressant Treatment ◽

Cost Effectiveness Analysis ◽

Adult Patients ◽

Major Depressive ◽

Effectiveness Analysis

Download Full-text

PMH13 COST-EFFECTIVENESS ANALYSIS OF SINGLE-DOSE EXTENDED RELEASE METHYLPHENIDATE (CONCERTA®) VS. ATOMOXETINE AND SHORT-ACTION METHYLPHENIDATE, FOR THE MANAGEMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY IN MEXICO

Value in Health ◽

10.1016/s1098-3015(10)68766-9 ◽

2007 ◽

Vol 10 (3) ◽

pp. A75

Author(s):

V Vazquez

Keyword(s):

Single Dose ◽

Cost Effectiveness ◽

Attention Deficit ◽

Attention Deficit Disorder ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

MS324 EXTENDED RELEASE NIACIN/LAROPIPRANT IS PROJECTED TO REDUCE CORONARY RISK BEYOND STATINS: COST-EFFECTIVENESS ANALYSIS IN SECONDARY PREVENTION PATIENTS IN GERMANY

Atherosclerosis Supplements ◽

10.1016/s1567-5688(10)70825-4 ◽

2010 ◽

Vol 11 (2) ◽

pp. 174

Author(s):

G.V. Michailov ◽

G.M. Davies ◽

B.M. Ambegaonkar ◽

K.J. Krobot

Keyword(s):

Cost Effectiveness ◽

Secondary Prevention ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Coronary Risk ◽

Effectiveness Analysis

Download Full-text

PUK2 COST-EFFECTIVENESS ANALYSIS OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)66140-2 ◽

2004 ◽

Vol 7 (6) ◽

pp. 798

Author(s):

D Castro ◽

J Soto ◽

I Exposito

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Extended Release ◽

Immediate Release ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text